Do you want to read an article? Please log in or register.
Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial
Lung Cancer
COMMENTED
Related content
Lung Cancer
Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study
Clin Lung Cancer
Reinmuth N, Goldman JW, Chen Y, Hotta K, Trukhin D, Statsenko G, Hochmair M, Özgüroğlu M, Ji JH, Garassino MC, Poltoratskiy A, Verderame F, Havel L, Bondarenko I, Losonczy G, Conev N, Kummer S, Mann H, Chugh P, Dalvi T, Paz-Ares L
doi: 10.1016/j.cllc.2025.08.001
Respiratory Tract Infection
Final survival analysis of induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma: a multicenter, randomized, phase 3 trial
Nat Commun
Cao X, Zhou JY, Huang HY, Guo L, Huang YY, Qiu WZ, Lin ZC, Cao KJ, Mo HY, Li XM, Li ZH, Han F, He YX, Liu YM, Bai YR, Wu SX, Ke LR, Chen X, Liang CX, Luo ZY, Xia Y, Deng Y, Miao JJ, Xia WX, Liang H, Zhao C, Xiang YQ, Guo X, Lv X
doi: 10.1038/s41467-026-69315-1
RECOMMENDED
Lung Cancer
Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
ESMO Open
Girard N, Bar J, Baas P, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido Lopez P, Gregorc V, Haakensen VD, Hiltermann TJN, Kao S, McDonald F, Mornex F, Moskovitz M, Peters S, Siva S, Solomon B, Qiao Y, Anand S, Chander P, Shcherbakova T, Diaz Perez I, Filippi AR
doi: 10.1016/j.esmoop.2026.106070
Lung Cancer
Durvalumab, carboplatin, and etoposide in patients who are treatment-naive with extensive-stage small-cell lung cancer and poor performance status (NEJ045A): a single-arm phase 2 trial
Lancet Respir Med
Asao T, Saida Y, Watanabe S, Kisohara A, Kishi K, Morita R, Nakagawa T, Tsukita Y, Furuya N, Miyawaki T, Ishikawa N, Yamada T, Tanaka T, Morita S, Kikuchi T, Maemondo M, Kobayashi K, North East Japan Study Group
doi: 10.1016/S2213-2600(25)00240-1
Lung Cancer
Real-World Clinical Outcomes of Concurrent Chemotherapy and Dose-Escalated Twice-Daily Radiotherapy With Simultaneous Integrated Boost (SIB) for Limited-Stage Small Cell Lung Cancer
Clin Lung Cancer
Celikarslan S, Sezen D, Duman M, Durankus NK, Oymak SE, Esen CSB, Rustamov A, Nasir A, Guclu SB, Kanıtez M, Kaban K, Yumuk F, Selcukbiricik F, Mandel NM, Cesur E, Erus S, Tanju S, Dilege S, Gumus T, Atasoy C, Demirkurek C, Falay O, Demirkol O, Bulutay P, Firat P, Atagun Y, Selek U
doi: 10.1016/j.cllc.2026.03.010
Lung Cancer
A Phase II Study of Accelerated Hyperfractionated Thoracic Radiotherapy With Dose Escalation to 54 Gy With Concurrent Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Long-Term Results at a Single Institution
Clin Lung Cancer
Matsuura K, Komaki R, Kono M, Kudo T, Ono A, Kameoka T, Shintani I, Kusaba H, Kawakubo A, Ando Y, Nishihara K, Iwamoto Y, Shoda H, Katsuta T, Kagemoto M
doi: 10.1016/j.cllc.2025.09.003
RECOMMENDED
Lung Cancer
Characterizing Risk Factors and Outcomes in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer Who Do Not Complete, or Who Experience Progression During/Within 42 Days of, Concurrent Chemoradiotherapy: The POSITION Study
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
Clin Lung Cancer
Mountzios G, Weng JK, Zairi E, Hsieh K, Chander P, Dunlop W, Qiao Y, Wang A, Januszewski A
doi: 10.1016/j.cllc.2026.01.005
RECOMMENDED
Lung Cancer
The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study Results
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
Clin Lung Cancer
Morgillo F, Del Signore E, Bria E, de Marinis F, Ciardiello F, Garassino MC, Stefani A, Verderame F, Morabito A, Sbrana A, Tonini G, Gilli M, Berardi R, Taveggia PA, Bearz A, Delmonte A, Migliorino MR, Gridelli C, Fadda GM, Iero M, Ardizzoni A
doi: 10.1016/j.cllc.2025.07.003
Lung Cancer
Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial
Lancet Respir Med
Spigel DR, Westeel V, Anderson IC, Greillier L, Guisier F, Bylicki O, Badin FB, Rousseau-Bussac G, Deldycke C, Griesinger F, Bograd A, Zhong W, Le Treut J, Van Hulst S, Gandara DR, Reck M, Hoffknecht P, Gubens MA, Crowley J, von der Leyen H, Woodard GA, Jablons DM, Kratz JR, Mann MJ, AIM-HIGH investigators
doi: 10.1016/S2213-2600(25)00213-9